INTERNATIONAL LIVER CANCER ASSOCIATION
International Liver Cancer Association 15th Annual ConferenceSeptember 2 - 5, 2021 Virtual Conference
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P-01 | Temporal and Spatial Dynamics of Hepatic Stellate Cell Activation in Intrahepatic Cholangiocarcinoma | Liqin Zhu |  Received |
 |
|||
| P-02 | Intra-tumoral epigenetic heterogeneity and aberrant molecular clocks in hepatocellular carcinoma | Paula Restrepo | Received |
|
|||
| P-03 | Autoimmunity and cancer immunosurveillance in the biliary tree | Jonathan Pol | Received |
|
|||
| P-04 | Inflamed class of HCC: an expansion of the immune class based upon new molecular features | Josep M. Llovet | Received |
|
|||
| P-05 | Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma. | Petros Fessas | Received |
|
|||
| P-06 | New therapeutic targets in cisplatin-resistant hepatoblastoma | Théo Hirsch | Received |
|
|||
| P-07 | Notch Pathway Activation Drives Immune Evasion in Hepatocellular Carcinoma | Katherine Lindblad | Received |
|
|||
| P-09 | Deep sequencing of HCC endothelium reveals an active role in immunosuppression and highlights the ectonucleotidase CD73 as a potential therapeutic target. | Rosemary Faulkes | Received |
|
|||
| P-10 | Activating Mucosal-Associated Invariant T cells (MAITs) in vivo as a Novel Target for Liver Cancer Immunotherapy | Benjamin Ruf | Received |
|
|||
| P-11 | The TUMOR SUPPRESOR ROLE OF THE a1-Na/K-ATPase/Src-p/PI3K SIGNALOSOME in NASH Related Hepatocellular Carcinoma: A TRANSLATIONAL STUDY. | Juan Sanabria | Received |
|
|||
| P-12 | Interplay between EZH2 and OGT in hepatocellular carcinoma | Margot Thirion | Received |
|
|||
| P-14 | Molecular characterization of HCC in Mongolia delineates unique genomic features | Laura Torrens | Received |
|
|||
| P-15 | Exogenous Antioxidants, N-acetylcysteine and Glutathione, Enhance Cancer Initiation and Growth in Hepatocellular Carcinoma | Vanilla Xin Zhang | Received |
|
|||
| P-16 | Dual mechanisms mediated by specific transcription factors and RalGAPA2 activates RalA signaling to support HCC development | LU TIAN | Received |
|
|||
| P-17 | Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. | David Pinato | Received |
|
|||
| P-18 | Portal vein thrombosis in HCC patients infected with COVID-19 | Mohamed Elgazzar | Received |
|
|||
| P-19 | Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma | Jordi Abril-Fornaguera | Received |
|
|||
| P-20 | Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver: A Spanish multicentre study | Marta Romero-Gutiérrez | Received |
|
|||
| P-21 | PROGNOSIS OF PATIENTS WITH OTHER PRIMARY TUMORS ASSOCIATED TO HEPATOCELULLAR CARCINOMA. | Miriam Celada | Received |
|
|||
| P-22 | Geographic, linguistic, and cultural factors are associated with clinical presentation, receipt of treatment, and survival of patients with hepatocellular carcinoma | Belaynew Taye | Received |
|
|||
| P-23 | Hepatic elastometry and risk of recurrence after HCC resection | PAULINE TORTAJADA | Received |
|
|||
| P-24 | Association of whole grains and dietary fiber intake with risk of liver cancer and chronic liver diseases in the NIH-AARP Diet and Health Study | Xing Liu | Received |
|
|||
| P-25 | Gene Set adaptation through graph generation enhances signature discrimination power and validates metabolism-related prognostic signatures in Hepatocellular Carcinoma | Josepmaria Argemi | Received |
|
|||
| P-26 | EXTERNAL VALIDATION OF THE INTEGRATED LIVER INFLAMMATORY SCORE (ILIS) AS A PROGNOSTIC INDEX IN PATIENTS WITH HEPATOCELLULAR CARCINOMA | Miriam Celada | Received |
|
|||
| P-28 | Undernutrition in patients with primary hepatocellular carcinoma | Hitomi Takada | Received |
|
|||
| P-29 | Dual filtration system for isolation and single cell RNA sequencing of circulating tumor cells and clusters in hepatocellular carcinoma: a pilot study | Vincent Chen | Received |
|
|||
| P-30 | The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. | Ambreen Muhammed | Received |
|
|||
| P-31 | Clinicopathological characterization of steatohepatitic variant of hepatocellular carcinoma (SH-HCC). | Loc TRAPANI | Received |
|
|||
| P-34 | Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON | Masatoshi Kudo | Received |
|
|||
| P-35 | The Efficacy and Prognostic Factors of TACE Combined with Apatinib in the Treatment of BCLC stage C Hepatocellular Carcinomas | Weifu LV | Received |
|
|||
| P-36 | A Pilot Study of the combination of Immune Checkpoint Inhibition with Ablation in Subjects with Hepatocellular Carcinoma; an evaluation of Trans-arterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) | Rebecca Wetzel | Received |
|
|||
| P-37 | A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL. | Thomas Talbot | Received |
|
|||
| P-38 | Impact of metabolic syndrome and non-alcoholic fatty liver disease in outcomes and tolerance after percutaneous multibipolar radiofrequency ablation for early hepatocellular carcinoma | Thi Thu Nga Nguyen | Received |
|
|||
| P-41 | Early antibiotic exposure is not detrimental to response to immune checkpoint inhibitor therapy for hepatocellular carcinoma: evidence from an observational study. | Petros Fessas | Received |
|
|||
| P-42 | Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Treatment of Intra-hepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial | Stephen Lam CHAN | Received |
|
|||
| P-43 | The Number of Small Hepatocellular Carcinoma Nodules in Patients Listed for Liver Transplantation within the Alpha-Fetoprotein Score Is a Prognostic Risk Factor | Alina Pascale | Received |
|
|||
| P-45 | Real-world outcomes of patients with hepatocellular carcinoma treated with transarterial radioembolization: results from CIRT, a large European prospective multi-centre observational study | Frank Kolligs | Received |
|
|||
| P-46 | Exploratory Network Meta-analyses of Selective Internal Radiation Therapy versus Sorafenib, Lenvatinib, and Atezolizumab-Bevacizumab as First-line Treatment in Subgroups of Patients with Hepatocellular Carcinoma | Richard Pollock | Received |
|
|||
| P-47 | Previous/Concurrent Radiation Enhanced the Efficacy of Immunotherapy in Metastatic and Recurrent Liver Cancer: A Pilot Study from the Real-world Data | Bo Chen | Received |
|
|||
| P-48 | Progression patterns and clinical outcomes following immune checkpoint inhibition for hepatocellular carcinoma (HCC): a multi-institutional international study. | Thomas Talbot | Received |
|
|||
| P-49 | Identification of Regorafenib Prognostic index (REP index) via recursive partitioning analysis in Advanced Hepatocellular Carcinoma Patients Receiving systemic treatment. | margherita rimini | Received |
|
|||
| P-50 | Impact of previous surgery on prognosis in patients with cholangiocarcinoma under chemotherapy | margherita rimini | Received |
|
|||
| P-51 | Free Androgen Index Levels May Influence the Trans-arterial Chemoembolization with Doxorubicin-Eluting Beads Response in Hepatocellular Carcinoma Patients: Preliminary Results. | Silvia Acosta-Lopez | Received |
|
|||
| P-53 | A humanized Claudin-1-specific monoclonal antibody for treatment of hepatocellular carcinoma | Marion Muller | Received |
|
|||
| P-54 | Emerging role of circulating miR-23b-3p and tissue miR-193a-3p as potential innovative biomarkers for human hepatocellular carcinoma. | Ilaria Grossi | Received |
|
|||
| P-55 | Lifestyle changes in DAA-cured Hepatitis C patients with advanced liver disease included in a nurse-led liver cancer screening program | Gemma Iserte | Received |
|
|||
| P-57 | Early SARS-CoV-2-related mortality of liver cancer patients: Cancer stage matters. | Sergio Muñoz-Martínez | Received |
|
|||
| P-58 | Deciphering Liver Cancer Tissue Organization by 3D Electron Microscopy and machine learning | Christophe Grosset | Received |
|
|||
| P-59 | Low baseline plasma L-Glutamine concentration identifies hepatocellular carcinoma patients at high risk of developing early gastrointestinal adverse events during sorafenib treatment. | Loreto Boix | Received |
|
|||
| P-60 | Efficacy and Safety of Lenvatinib in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Retrospective Analysis | KyungHye Bang | Received |
|
|||
| P-61 | Novel management score of systemic therapy for hepatocellular carcinoma patients | Issei SAEKI | Received |
|
|||
International Liver Cancer Association 15th Annual Conference
September 2 - 5, 2021 Virtual Conference
|
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 19/08/2021 TO 02/09/2022
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
